Suppr超能文献

人血小板裂解物维持脐带间充质基质细胞的干性并促进大鼠支气管肺发育不良中的肺修复。

Human Platelet Lysate Maintains Stemness of Umbilical Cord-Derived Mesenchymal Stromal Cells and Promote Lung Repair in Rat Bronchopulmonary Dysplasia.

作者信息

Liao Guilian, Liao Yan, Li Duanduan, Fu Zeqin, Wu Shiduo, Cheng Danling, Ouyang Qiuxing, Tang Zan, Zeng Guifang, Liang Xiao, Xu Shaokun, Hu Junyuan, Liu Muyun

机构信息

Obstetrics and Gynecology, Maternal and Child Health Hospital of Longgang District, Shenzhen, China.

Shenzhen Beike Biotechnology Co., Ltd., Shenzhen, China.

出版信息

Front Cell Dev Biol. 2021 Nov 10;9:722953. doi: 10.3389/fcell.2021.722953. eCollection 2021.

Abstract

Mesenchymal stromal cells (MSCs) show potential for treating preclinical models of newborn bronchopulmonary dysplasia (BPD), but studies of their therapeutic effectiveness have had mixed results, in part due to the use of different media supplements for MSCs expansion . The current study sought to identify an optimal culture supplement of umbilical cord-derived MSCs (UC-MSCs) for BPD therapy. In this study, we found that UC-MSCs cultured with human platelet lysate (hPL-UCMSCs) were maintained a small size from Passage 1 (P1) to P10, while UC-MSCs cultured with fetal bovine serum (FBS-UCMSCs) became wide and flat. Furthermore, hPL was associated with lower levels of senescence in UC-MSCs during expansion compared with FBS, as indicated by the results of β-galactosidase staining and measures of senescence-related genes (CDKN2A, CDKN1A, and mTOR). In addition, hPL enhanced the proliferation and cell viability of the UC-MSCs and reduced their doubling time . Compared with FBS-UCMSCs, hPL-UCMSCs have a greater potential to differentiate into osteocytes and chondrocytes. Moreover, using hPL resulted in greater expression of Nestin and specific paracrine factors (VEGF, TGF-β1, FGF2, IL-8, and IL-6) in UC-MSCs compared to using FBS. Critically, we also found that hPL-UCMSCs are more effective than FBS-UCMSCs for the treatment of BPD in a rat model, with hPL leading to improvements in survival rate, lung architecture and fibrosis, and lung capillary density. Finally, qPCR of rat lung mRNA demonstrated that hPL-UCMSCs had lower expression levels of inflammatory factors (TNF-α and IL-1β) and a key chemokine (MCP-1) at postnatal day 10, and there was significant reduction of CD68 macrophages in lung tissue after hPL-UCMSCs transplantation. Altogether, our findings suggest that hPL is an optimal culture supplement for UC-MSCs expansion , and that hPL-UCMSCs promote lung repair in rat BPD disease.

摘要

间充质基质细胞(MSCs)在治疗新生儿支气管肺发育不良(BPD)的临床前模型方面显示出潜力,但关于其治疗效果的研究结果不一,部分原因是在MSCs扩增过程中使用了不同的培养基补充剂。本研究旨在确定用于BPD治疗的脐带源MSCs(UC-MSCs)的最佳培养补充剂。在本研究中,我们发现用人血小板裂解液培养的UC-MSCs(hPL-UCMSCs)从第1代(P1)到第10代保持较小的尺寸,而用胎牛血清培养的UC-MSCs(FBS-UCMSCs)则变得宽大扁平。此外,与FBS相比,hPL与UC-MSCs扩增过程中较低的衰老水平相关,β-半乳糖苷酶染色结果和衰老相关基因(CDKN2A、CDKN1A和mTOR)的检测表明了这一点。此外,hPL增强了UC-MSCs的增殖和细胞活力,并缩短了它们的倍增时间。与FBS-UCMSCs相比,hPL-UCMSCs具有更大的分化为骨细胞和软骨细胞的潜力。此外,与使用FBS相比,使用hPL导致UC-MSCs中巢蛋白和特定旁分泌因子(VEGF、TGF-β1、FGF2、IL-8和IL-6)的表达更高。至关重要的是,我们还发现,在大鼠模型中,hPL-UCMSCs在治疗BPD方面比FBS-UCMSCs更有效,hPL可提高存活率、改善肺结构和纤维化以及肺毛细血管密度。最后,对大鼠肺mRNA进行的qPCR显示,在出生后第10天,hPL-UCMSCs的炎症因子(TNF-α和IL-1β)和关键趋化因子(MCP-1)的表达水平较低,并且在hPL-UCMSCs移植后肺组织中的CD68巨噬细胞显著减少。总之,我们的研究结果表明,hPL是UC-MSCs扩增的最佳培养补充剂,并且hPL-UCMSCs可促进大鼠BPD疾病中的肺修复。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b1/8631747/375dafd9575b/fcell-09-722953-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验